Evidence map›Paper›PMID 24022761›Full record

ArticleMolecules (Basel, Switzerland)2013

Retraction: Al-Salahi, R.A. et al. Cytotoxicity and anti-inflammatory activity of ethylsulfanyltriazoloquinazolines. Molecules 2013, 18, 1434-1446.

Shu-Kun Lin

Abstract readRetraction Notice
In one paragraph

Article in Molecules (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Shu-Kun LinPublisher of Molecules, Multidisciplinary Digital Publishing Institute (MDPI), Klybeckstrasse 64, Basel CH-4057, Switzerland. lin@mdpi.com

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have been made aware of the fact that a large proportion of the Introduction section and corresponding references of the title paper [1] had been copied verbatim from an earlier paper by Hamdy and Gamal-Eldeen [2], and further, during our investigation it has also come to light that most of the text in question had been lifted unchanged from an even earlier review paper by a different group [3]. The authors have been contacted, these facts confirmed, and Dr. Amira M. Gamal-Eldeen has been identified as the person responsible for contributing that part of the paper. As a member of the Committee on Publication Ethics (COPE), MPDI takes very seriously the responsibility to enforce a rigorous peer-review process together with strict ethical policies and standards to ensure the addition of high quality scientific works to the field of scholarly publication. In addition to an infringement of the Elsevier and American Association for Cancer Research copyright on the previous publications, this is also a clear violation of our policy to only publish new, previously unpublished material, so this paper is declared retracted and shall be marked accordingly for the scientific record. We cannot comment on any of the scientific data contained in the Molecules paper, which to the best of our knowledge is original. We would like to apologize to our readership on behalf of the Molecules editorial team for the fact this event went undetected during the peer-review and pre-publication processing of the paper and for any inconvenience caused by this event.

Identifiers

PMID24022761
PMCPMC6270130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.